215

REFERENCES

1. Evaluate pharma, World Preview to 2016, May 2010.2. IMS Health Forecasts 2011 Pharma Market Growth, Dec 2010.3. Pharma Prognosis, Citigroup Global Markets, Industry, Oct 20094. IMS Market Prognosis, Apr 2011.5. The Global Use of Medicines: Outlook Through 2015, Report by

the IMS Institute for Healthcare Informatics, May 2011.6. Zacks Equity, Pharmaceutical Industry Outlook - Mar 20117. World Preview 2016 Evaluate Pharma, Jun 2011

216

8. World Review, 2005, Pharma Strategy Group, 20059. IMS Health, National Sales Perspectives, Sep 2010.10. Lofgren H, Reshaping Australian Drug Policy: The Dilemmas of

Generic Medicines Policy, Australia and New Zealand Healthpolicy 4. 1, 2007:11-14.

11. Kadonga S and Kanzler L, “Building Japan’s Generic-DrugMarket, “McKinsey Quarterly, Dec 2007.

12. Frank RG. The ongoing regulation of generic drugs. N Engl JMed. 357, 2007:1993-6.

13. IMS Health, Global pharmaceutical sales by Region- 2007, 2008.14. Savings. An economic analysis of Generic drug usage in the U.S.

Generic Pharmaceutical Association, 2011.15. E. Weisberg, Taming pharmacy: Driving out waste one consumer

at a time, “Express scripts, Presentation, May 27, 2008.16. IMS Health Canada, pharmaceutical Trends: Generic Dispensing

Trend by Province, Canada, 2007: 200817. H. Lofgren, Reshaping Australian Drug Policy: The Dilemmas of

Generic Medicines Policy, Australia and New Zealand Healthpolicy 4. 1, 2007:11-14

18. S. Kadonga and L Kanzler, Building Japan’s Generic-DrugMarket, McKinsey Quarterly, Dec 2007

19. European Generic Medicine Association. The Role of GenericMedicines in Europe, Sep 2007.

20. J.S. Haas, K. A. Phillips, E.P. Gerstenberger et al., PotentialSavings from Substituting Generic Drugs for Brand-NameDrugs: Medical Expenditure Panel Survey, 1997-2000, Annals ofInternal Medicine, 142:891-897.

21. K. Jaeger, Generic Medicines Are Key to Medical Reform,Pharmacy Times, 2005.

22. P. Leigh. Strategies to increase generic drug utilization andassociated service. AARP Public Policy Institute. 2008, 1-20.

23. National Association of Chain drug Stores, “Industry Facts-at-a-Glance, 2008.

24. A. Daemmrich, U.S. Healthcare Reform and the PharmaceuticalIndustry, Working Paper, 2011.

25. D. Long, U.S. Pharmaceutical Market Trends: A Picture ofIncreasing Trends, IMS Health 2009.

26. US Trade Stats Express, International Trade Administration,Govt. of USA.

Economic Analysis Generic Pharmaceuticals 1999-2008: $734Billion in Health Care Savings. GPhA Commissioned Analysis byIMS. May 2009.

217

27. 2006 Chain Pharmacy Industry Profile, The National Associationof Chain Drug Stores.

28. Express Scripts Study Shows Substantial Savings Opportunityfor Consumers, states, Health Care Purchasers with Generics,says GPhA, Generic Pharmaceutical Association, Press release,16, 2005.

29. Savings. An economic analysis of Generic drug usage in the U.S.Generic Pharmaceutical Association (GPhA), Sep 2011.

30. D. Long. The US Pharmaceutical Market: Trends, Issues, &Outlook, IMS Jan 2011.

31. W. Greene. The Emergence of India’s Pharmaceutical Industryand Implications for the U.S. Generic Drug Market, 2007.

32. C Chatterjee, New Suppliers & New Markets: Essays on theGlobal Pharmaceutical Industry, July 2009. Public Policy andManagement Dissertation thesis.

33. S. Chauhduri. 2005, The WTO and India. PharmaceuticalIndustry, Oxford University Press, New Delhi, India.

34. HN. Joshi. Analysis of the Indian Pharmaceutical Industry withEmphasis on Opportunities in 2005, PharmaceuticalTechnology. 2003: 74-94.

35. A. Chadha, Product cycles, Innovation, and Exports: A study ofIndian Pharmaceuticals, World Development. 37, 2009: 1478-1483.

36. R. Chittoor, S. Ray. Internationalisation paths of IndianPharmaceutical firms – A strategic group analysis, Journal ofInternational Management. 13, 2007: 338-355.

37. Pharmexcil, 7th Annual Report, 2010-2011.38. B. Poduri B, U. Vasireddy, JD Kumar, S. Lanka. Dominance of

European Union in World Pharmaceutical Trade, Journal ofPharmaceutical Science and Technology Vol. 3(4) 2011: 575-585.

39. Nagaraj Naidu's speech at India-China Pharma Conference inShanghai - Jun 2011

40. PricewaterhouseCoopers. Global Pharmaceutical CompaniesNeed To Take An Even Closer Look At India, 2010 News Release.

41. Ellen F.M.’t Hoen, LL.M., The Global Politics of PharmaceuticalMonopoly Power, AMB 2009.

42. N. Nattrass. Government Leadership and ARV Provision inDeveloping Countries. Centre for social science research AIDSand society research unit. Working paper no. 14.

43. S. Kannan. Testing times for India's pharma industry, AsiaTimes, 2005.

44. S. Guenni. Industrial and health related aspects of a global IPRregime in developing countries: case studies from the South,Working Paper, No 7, 2006.

218

45. S. Aaron. “73 Generic drugs concoct their next move,” CNNMoney, Feb. 9, 2007.

46. DP Dubey. Globalization and its impact on the IndianPharmaceutical Industry, 1999.

47. IHS Global Insight, Increasing Demand for Indian DrugsPrompts Calls for Permanent U.S. FDA Presence in India, 2007.

48. K. Kate. India and China forge ahead while Europe plays catch-up. Generics bulletin, 2011: 20-22.

49. JD Kumar, M. Vishwajeet, PV Appaji, S. Lanka, B. Poduri.Presence of Indian pharmaceutical industries in US market: Anempirical analysis, Journal of Generic Medicines. 6(4), 2009:333–344.

50. Department of Commerce, Ministry of Commerce and Industry,Government of India. Report of the Task Force, ‘strategy forIncreasing Exports of Pharmaceutical Products, 2008.

51. T.Ramesh, D.Saravanan et al., Regulatory Perspective forEntering Global Pharma Markets, Pharma Times. 43(9),2011:15-20.

52. Rick Ng. Drugs From Discovery to Approval. John Wiley & Sons,Hoboken, 2004, 211.

53. L. Shargel and I. Kanfer. Generic Drug Development, InformaHealthcare 2004, 211–225.

54. Interview with Sue Capie. CEO. PharmaVantage. 2009.55. J. Bumpas and E. Betsch. Exploratory Study on Active

Pharmaceutical Ingredient Manufacturing for EssentialMedicines, 2009.

56. H. Grabowski, I. Cockburn and G. Long. The Market For Follow-On Biologics: How Will It Evolve? Health Affairs, 25, 2006: 1291-1301. 505(b)(2) Application, S. Weinberg, GuideBook for DrugRegulatory Submission, John Wiley & Sons, Inc., 2009, 191-194.

57. DO. Beers. Generic and Innovator drugs: A Guide to FDAapproval Requirements. Aspen Publishers, Inc., 2004, App. 35-8.

58. R. Khullar, A. Goel, G. Aggarwal. Generic Drugs-A GroundDiscussion, Int. J. Drug Dev. & Res., 3, 2011: 178-184.

59. GJ. Mossinghoff, "Overview of the Hatch-Waxman Act and ItsImpact on the Drug Development Process," Food and Drug LawJournal 54(2), 1999:187–194.

60. LS. Welage, et al. Understanding the issues Scientific IssuesEmbedded in the Generic Drug Approval Process. J Am PharmAssoc. 41(6), 2001:856-867.

61. Food and Drug Administration. Requirements for Submission ofIn Vivo Bioequivalence Data. Federal Register 2003a, 68:640

219

62. M. Michelle. Greater Access to Generic Drugs: New FDAInitiatives to Improve Drug Reviews and Reduce Legal Loopholes.FDA Consumer, 37, 2003.

63. WO. Foye, Thomas L. Lemke, et al., Foye's principles ofmedicinal chemistry, Lippincott Williams & Wilkins. 335

64. Chow SC. Individual bioequivalence: A review of the FDA draftguidance. Drug Information Journal, 33, 1999:435-444.

65. Harris Interactive Inc., Attitudes and Beliefs About the Use ofOver-the-Counter Medicines: A Dose of Reality, 2002: 1-26.

66. U.S. Patent and Trademark Office. “General InformationConcerning Patents: Nature of Patent and Patent Rights.”Available online at http://www.uspto.gov/go/pac/doc/general/.Accesssed on July 27, 2007.

67. H. Don and T. Foster. “The Orange Book: The Food and DrugAdministration’s Advice on Therapeutic Equivalence,” AmericanPharmacy Journal, NS30 (7), 1990: 403-405.

68. GJ. Glover. The Influence of Market Exclusivity on DrugAvailability and Medical Innovations. AAPS Journal.2007; 9(3): E312-E316.

69. JR. Sanjuan. U.S and E.U Protection of Pharmaceutical TestData, Consumer Project on Technology, 2006: 1-25.

70. ES. Weiswasser and SL. Cunningham, 180-day exclusivity ishotly contested, The National Law Journal, April 2002: 1-2.

71. Generic Initiative for Value and Efficacy (GIVE) page. U.S. Foodand Drug Administration Web site. Available at:http://www.fda.gov/oc/initiatives/advance/generics.html.Accessed October 22, 2007.

72. Drug Price Competition and Patent Term Restoration Act of1984, Pub. L. No. 98-417, 98 Stat.1585 (codified in scatteredsections of 21 U.S.C., 35 U.S.C., and 42 U.S.C.)

73. J. Nguyen. FDA’s New Generic Initiative for Value and Efficiency(GIVE). Health Matters, 2(5), 2007: Pg.2.

74. Federal Trade Commission, Generic Drug Entry Prior to PatentExpiration: An FTC Study, July 2002.http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf.

75. LE. Panattoni. The effect of Paragraph IV decisions and genericentry before patent expiration on brand pharmaceutical firms, JHealth Econ.; 30(1), 2011:126-45.

76. AM. Sokal , BA Gerstenblith. The Hatch-Waxman Act:encouraging innovation and generic drug competition, Curr TopMed Chem. 10(18), 2010:1950-9.

77. RD Huntington. Paragraph IV Litigation in the United States,Rothwell, Figg, Ernst & Manbeck, 2009.

78. ParagraphFour.com.

220

http://www.paragraphfour.com/explained/why_challenge.html(Accessed on 01.12.2011).

79. Federal Trade Commission, Generic Drug Entry Prior to PatentExpiration: An FTC Study, July 2002.

80. J. Brown, Quick Uptake: Generic Competitors have DevouredProzac Sales Faster than Eli Lilly Marketers Had Anticipated,Med Ad News, December 2001, 26.

81. S Koliopoulos, T Hung, A Pollack, S Grehan. Brand Erosion byGenerics. EP Publications, BE403P1 - BE403P3

82. T. Wani, Patient’s Access to Pills: Fight between Generic andBrand-name Drugs Continues, Indian J. Intell. Prop. L.,2009:102-115

83. 3rd Edition, Patent Awards, Pharmexcil, 2010-11.84. SP. Brooks. Markov Chain Monte Carlo and Its Application.

Journal of the Royal Statistical Society, 47(1), 1998: 69-100.85. I. Michael. Orlov, Multiple Linear Regression Analysis Using

Microsoft Excel, 1996.86. IMS Health, National Sales Perspectives, December 2010. Report

by the IMS Institute for Healthcare Informatics.http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/2010_Top_Therapeutic_Classes_by_Sales.pdf (last accessed on 25.12.2011).

87. Movers and Shakers, A Review of Pharma Matters Report, April -June 2011. Thomson Reuters.http://thomsonreuters.com/content/science/pdf/ls/pharma_matters/movers_shakers-cwp-en_issue16.pdf (Accessed on01.12.2011)

88. JD Kumar, V Mohan, PV Appaji, L Srinivas, P Balaram. Presenceof Indian pharmaceutical industries in US market: An empiricalanalysis, Journal of Generic Medicines. 6(4), 2009: 333–344.

89. M. Sawant. Opportunity for India in the World Generics Market,Frost & Sullivan,http://pharmalicensing.com/public/articles/view/1144147543_44324e57b031f/opportunity-for-india-in-the-world-generics-market (last accessed on 24.11.2010)

90. IHS Global Insight. World Review, 2005, Pharma StrategyGroup, 2005 ibid.

91. Generic Pharmaceuticals Association, Biogenerics, GPhAPosition. http://www.gphaonline.org/issues/biogenerics (lastaccessed on 24.11.2010)

92. Strides Arcolab expands in biologics, buying 70% stake inBangalore’s Inbiopro, The PharmaLetter, 2010.http://www.thepharmaletter.com/file/100553/strides-arcolab-expands-in-biologics-buying-70-stake-in-bangalores-inbiopro.html (last accessed on 17.12.2011)